MAPK1 and acute promyelocytic leukemia: Similarly, treatment of NB-4 acute promyelocytic leukemia cells with arsenic trioxide resulted in the activation of the p38 MAPK, which activated the protein kinase 2 pathway, whereas pharmacological inhibition of p38 further enhanced arsenic trioxide-induced apoptosis and growth inhibition of APL which have not been well specified.   54